ホーム
すべてのリソース

Preparing for, Surviving and Thriving in a Consolidating Pharmaceutical Industry

Written by Samantha Schwab

Updated: Apr 11, 2021

Authors
More from the author

By Jamie Weissglass

Preparing for, Surviving and Thriving in a Consolidating Pharmaceutical Industry, Screenshot, Front Page

The pharmaceutical industry is experiencing heightened merger and acquisition activity, due in large part to rising competition, increasing regulatory challenges and expiring patents’ periods of exclusivity. In 2018, the industry saw 248 mergers worth approximately $198 billion; one law firm predicts that the value of transactions will soar to $331 billion in 2019.

In the course of these transactions, many pharmaceutical companies have encountered information governance challenges that they did not anticipate—or budget for—prior to the merger. As they begin to assess the disparate data source landscapes in an effort to unify their systems, issues in their document retention, preservation and retrieval become readily apparent, requiring a substantial amount of time and monetary investment to resolve—resources that are typically scarce after a transaction closes. This generally means that the necessitated data mapping, remediation and integration endeavors are deprioritized, leaving these combined organizations even more exposed in the event of litigation or a regulatory or compliance investigation.

This white paper takes a closer look at the status of mergers and acquisitions in the pharmaceutical industry, the challenges that these transactions exacerbate for the combined companies and solutions for mitigating those risks.

Read the Full Whitepaper.

By Jamie Weissglass

Preparing for, Surviving and Thriving in a Consolidating Pharmaceutical Industry, Screenshot, Front Page

The pharmaceutical industry is experiencing heightened merger and acquisition activity, due in large part to rising competition, increasing regulatory challenges and expiring patents’ periods of exclusivity. In 2018, the industry saw 248 mergers worth approximately $198 billion; one law firm predicts that the value of transactions will soar to $331 billion in 2019.

In the course of these transactions, many pharmaceutical companies have encountered information governance challenges that they did not anticipate—or budget for—prior to the merger. As they begin to assess the disparate data source landscapes in an effort to unify their systems, issues in their document retention, preservation and retrieval become readily apparent, requiring a substantial amount of time and monetary investment to resolve—resources that are typically scarce after a transaction closes. This generally means that the necessitated data mapping, remediation and integration endeavors are deprioritized, leaving these combined organizations even more exposed in the event of litigation or a regulatory or compliance investigation.

This white paper takes a closer look at the status of mergers and acquisitions in the pharmaceutical industry, the challenges that these transactions exacerbate for the combined companies and solutions for mitigating those risks.

Read the Full Whitepaper.

以下のフォームに記入して、詳細なインサイトをダウンロードしてください。

Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Côte d'Ivoire
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Consilioの最新情報にサインアップ

ロレム・イプサム・ドロール・シット・メット、コネクター・ディピッシング・エリット。様々なものを悲惨な要素にぶつけます。
ありがとう!提出物が受理されました!
「サインアップ」をクリックすると、当社に同意したものとみなされます プライバシーポリシー
おっと!フォームの送信中に問題が発生しました。